Enthusiasm for dried blood spot samples is building among clinical proteomic researchers and companies, but recent work suggests technical hurdles remain.
They acknowledge that while the technical hurdles of proteomic test development have become manageable, commercialization is still a major challenge.
With Medicare coverage for the test in place, the company is hoping it will surpass the limited commercial success of its initial Xpresys Lung offering.
Both published last month, the studies looked at, respectively, early-stage discovery of lung cancer markers and development of a clinical test for the disease.
Palmetto GBA has issued a draft local coverage determination for the company's Xpresys Lung 2 lung cancer test, an update version of its original Xpresys test.
The Medicare contractor is proposing to not cover Vectra DA, but to extend coverage for Prolaris, Xpresys, and DecisionDx-UM under specific circumstances.
The study found that with use of the mass spec-based test, about a third of surgeries and total invasive procedures, including biopsies, could be avoided.
The study suggests Indi's Xpresys test could be useful in physician decision making but raises questions about the extent to which doctors will follow its recommendations.
Company researchers showed that the agents could selectively target single point mutations not associated with protein-binding pockets.
Many of the meeting's proteomics presentations concerned not so much mass spec analysis itself as the refinement of processes and workflows leading up to it.
CNN reports that researchers have tied a new variant to opioid addiction risk.
Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.
An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.
In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.